Andrew D. Goodman, MD is Professor of Neurology, Chief of the Neuroimmunology Unit, and Director of the Multiple Sclerosis Center at the University of Rochester.

Dr. Goodman is a graduate of Rutgers College and the University of Medicine and Dentistry of New Jersey; he did residency training in internal medicine and neurology at Mt. Sinai Medical Center in New York City. He completed a research fellowship in the Neuroimmunology Branch at the National Institutes of Health, Bethesda, Maryland.

Numerous publications reflect his interests in clinical and experimental therapeutics research as well as the immunology and virology of multiple sclerosis. Dr. Goodman has been principal investigator and a member of national and international steering committees for numerous clinical trials of new therapies for multiple sclerosis.

Dr. Goodman is a past Chair of the Multiple Sclerosis Section of the American Academy of Neurology. He has served the National Multiple Sclerosis Society as Deputy Medical Officer, Co-Chair of the Long-term Care Committee, member of the Client Education Committee, and member of the Executive Committee of the National Clinical Advisory Board.

Certified Specialties

Neurology - American Board of Psychiatry & Neurology

Faculty Appointments

Professor - Department of Neurology, Neuroimmunology (SMD)

Credentials

Residency & Fellowship

Fellowship, Neurology, National Institutes of Health, NIH. 1983 - 1988

Residency, Internship/Residency, Mount Sinai Hospital. 1979 - 1980

Residency, Resident, Mount Sinai Hospital. 1979 - 1983

Education

MD | Rutgers New Jersey Medical School. 1979

Awards

Fellow, American Academy of Neurology. 2005

Impact Presentation Award, Congress of the European Committee for Treatment and Research in Multiple Sclerosis. 2004

Senior Faculty Award. 2003

Inductee, Volunteer Hall of Fame. 2001

Chair, Multiple Sclerosis Section. 1999 - 2000

Chair-elect, Multiple Sclerosis Section. 1998 - 1999

Named in Best Doctors in America. 1998

University of Rochester Neurology Resident Faculty Teaching Award. 1997

Named in Best Doctors in America: Northeast.. 1996

Chief Neurology Resident. 1982 - 1983

Alpha Omega Alpha. 1979

A.B. with Distinction in Biochemistry. 1974

Henry Rutgers Scholar. 1973 - 1974

Research

Clinical Trials

A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-Nmda Receptor Encephalitis and Assess Markers of Disease,A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-Nmda Receptor Encephalitis and Assess Markers of Disease

Lead Researcher: Andrew D Goodman

Anti-N-methyl-D-aspartate receptor encephalitis is a life-threatening autoimmune disorder for which there are no approved therapies. This study will determine if the drug, Inebilizumab, will improve the disability of patients who have anti-N-methyl-D...

Publications

Journal Articles

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.

Lublin F, Miller DH, Freedman MS, Cree BA, Wolinsky JS, Weiner H, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BM, Merschhemke M, Li B, Putzki N, Liu FC, Häring DA, Kappos L,

Lancet.. 2016 March 12387 (10023):1075-1084. Epub 01/28/2016.

Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial.

Applebee A, Goodman AD, Mayadev AS, Bethoux F, Goldman MD, Klingler M, Blight AR, Carrazana EJ

Clinical therapeutics.. 2015 December 137 (12):2780-7. Epub 11/10/2015.

Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials.

Goodman AD, Bethoux F, Brown TR, Schapiro RT, Cohen R, Marinucci LN, Henney HR, Blight AR,

Multiple sclerosis : clinical and laboratory research.. 2015 September 21 (10):1322-31. Epub 01/12/2015.

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA,

Lancet.. 2012 November 24380 (9856):1829-39. Epub 11/01/2012.

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA,

Lancet.. 2012 November 24380 (9856):1819-28. Epub 11/01/2012.

Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance.

Kinkel RP, Dontchev M, Kollman C, Skaramagas TT, O'Connor PW, Simon JH,

Archives of neurology.. 2012 February 69 (2):183-90. Epub 10/10/2011.

Symptomatic management in multiple sclerosis.

Samkoff LM, Goodman AD

Neurologic clinics.. 2011 May 29 (2):449-63. Epub 1900 01 01.

Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks.

Morrow SA, O'Connor PW, Polman CH, Goodman AD, Kappos L, Lublin FD, Rudick RA, Jurgensen S, Paes D, Forrestal F, Benedict RH

Multiple sclerosis : clinical and laboratory research.. 2010 November 16 (11):1385-92. Epub 08/25/2010.

A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.

Goodman AD, Brown TR, Edwards KR, Krupp LB, Schapiro RT, Cohen R, Marinucci LN, Blight AR,

Annals of neurology.. 2010 October 68 (4):494-502. Epub 1900 01 01.

Assessment of JC virus DNA in blood and urine from natalizumab-treated patients.

Rudick RA, O'Connor PW, Polman CH, Goodman AD, Ray SS, Griffith NM, Jurgensen SA, Gorelik L, Forrestal F, Sandrock AW, E Goelz S

Annals of neurology.. 2010 September 68 (3):304-10. Epub 1900 01 01.

Broadening the spectrum of controls for skin biopsy in painful neuropathies.

Herrmann DN, O'Connor AB, Schwid SR, Da Y, Goodman AD, Rafferty J, Donahue S, Dworkin RH

Muscle & nerve.. 2010 September 42 (3):436-8. Epub 1900 01 01.

Dalfampridine in multiple sclerosis.

Goodman AD, Hyland M

Drugs of today.. 2010 September 46 (9):635-9. Epub 1900 01 01.

Rapid disease course in African Americans with multiple sclerosis.

Kister I, Chamot E, Bacon JH, Niewczyk PM, De Guzman RA, Apatoff B, Coyle P, Goodman AD, Gottesman M, Granger C, Jubelt B, Krupp L, Lenihan M, Lublin F, Mihai C, Miller A, Munschauer FE, Perel AB, Teter BE, Weinstock-Guttman B, Zivadinov R, Herbert J

Neurology.. 2010 July 2075 (3):217-23. Epub 1900 01 01.

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate.

Ford C, Goodman AD, Johnson K, Kachuck N, Lindsey JW, Lisak R, Luzzio C, Myers L, Panitch H, Preiningerova J, Pruitt A, Rose J, Rus H, Wolinsky J

Multiple sclerosis : clinical and laboratory research.. 2010 March 16 (3):342-50. Epub 01/27/2010.

A randomized trial of memantine as treatment for spasticity in multiple sclerosis.

Mehta LR, McDermott MP, Goodman AD, Schwid SR

Multiple sclerosis : clinical and laboratory research.. 2010 February 16 (2):248-51. Epub 12/22/2009.

Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.

Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R, Marinucci LN, Blight AR,

Lancet.. 2009 February 28373 (9665):732-8. Epub 1900 01 01.

GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study.

Goodman, AD; Rossman, H; Bar-Or, A; Miller, A; Miller, DH; Schmierer, K; Lublin, F; Khan, O; Bormann, NM; Yang, M; Panzara, MA; Sandrock, AW; GLANCE Investigators.

Neurology. 2009; 3(72(9)): 806-12.

Sustained-release oral fampridine in multiple sclerosis: a randomized double-blind, controlled trial.

Goodman AD; Brown TR; Drupp LB; Schapiro RT; Schwid SR; Cohen R; Marinucci LN; Blight AR; Fampridine MS-F203 Investigators.

Lancet. 2009; 28(373): 697-8.

Dose comparison trial of sustained-release fampridine in multiple sclerosis.

Goodman AD, Brown TR, Cohen JA, Krupp LB, Schapiro R, Schwid SR, Cohen R, Marinucci LN, Blight AR,

Neurology.. 2008 October 771 (15):1134-41. Epub 07/30/2008.

Neuromyelitis optica spectrum disorder in a patient with systemic lupus erythematosus and anti-phospholipid antibody syndrome.

Mehta LR, Samuelsson MK, Kleiner AK, Goodman AD, Anolik JH, Looney RJ, Schwid SR

Multiple sclerosis : clinical and laboratory research.. 2008 April 14 (3):425-7. Epub 01/21/2008.

Neuromyelitis optica spectrum disorder in a patient with Ssstemic lupus erythematosus and anti-phospholipid antibody syndrome.

Mehta LR; Smauelsson MK; Kleiner AK; Goodman AD; Anolik JA; Loney JR and Schwid SR.

Multiple Sclerosis. 2008; 14(3): 425-427.

Disease Modifying Therapies.

Mehta, LR and Goodman AD.

Continuum: Lifelong Learning in Neurology. 2008; 13(5): 144-80.

Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial.

Schwid SR, Goodman AD, Weinstein A, McDermott MP, Johnson KP,

Journal of the neurological sciences.. 2007 April 15255 (1-2):57-63. Epub 02/28/2007.

Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.

Cohen JA, Rovaris M, Goodman AD, Ladkani D, Wynn D, Filippi M,

Neurology.. 2007 March 2068 (12):939-44. Epub 1900 01 01.

Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study.

Goodman, AD.; Cohen, JA.; Cross, A.

Multiple Sclerosis. 2007; 2: 135-142.

Neutralizing anti-IFN-beta antibodies: how much more evidence do we need to use them in practice?

Giovannoni G, Goodman A

Neurology.. 2005 July 1265 (1):6-8. Epub 1900 01 01.

An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis.

Vollmer TL, Phillips JT, Goodman AD, Agius MA, Libonati MA, Giacchino JL, Grundy JS

Multiple sclerosis : clinical and laboratory research.. 2004 October 10 (5):511-20. Epub 1900 01 01.

Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects.

O'Connor PW, Goodman A, Willmer-Hulme AJ, Libonati MA, Metz L, Murray RS, Sheremata WA, Vollmer TL, Stone LA,

Neurology.. 2004 June 862 (11):2038-43. Epub 1900 01 01.

Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial.

Johnson KP, Brooks BR, Ford CC, Goodman AD, Lisak RP, Myers LW, Pruitt AA, Rizzo MA, Rose JW, Weiner LP, Wolinsky JS

Multiple sclerosis : clinical and laboratory research.. 2003 December 9 (6):585-91. Epub 1900 01 01.

Cognitive fatigue during a test requiring sustained attention: a pilot study.

Schwid SR, Tyler CM, Scheid EA, Weinstein A, Goodman AD, McDermott MP

Multiple sclerosis : clinical and laboratory research.. 2003 October 9 (5):503-8. Epub 1900 01 01.

Multiple sclerosis characteristics in African American patients in the New York State Multiple Sclerosis Consortium.

Weinstock-Guttman B, Jacobs LD, Brownscheidle CM, Baier M, Rea DF, Apatoff BR, Blitz KM, Coyle PK, Frontera AT, Goodman AD, Gottesman MH, Herbert J, Holub R, Lava NS, Lenihan M, Lusins J, Mihai C, Miller AE, Perel AB, Snyder DH, Bakshi R, Granger CV, Greenberg SJ, Jubelt B, Krupp L, Munschauer FE, Rubin D, Schwid S, Smiroldo J,

Multiple sclerosis : clinical and laboratory research.. 2003 June 9 (3):293-8. Epub 1900 01 01.

Accuracy and reproducibility of manual and semiautomated quantification of MS lesions by MRI.

Ashton EA, Takahashi C, Berg MJ, Goodman A, Totterman S, Ekholm S

Journal of magnetic resonance imaging : JMRI.. 2003 March 17 (3):300-8. Epub 1900 01 01.

Human Herpesvirus 6 Genome and Antigen in Acute Multiple Sclerosis Lesions.

Goodman, A.; Mock, D.; Powers, J.; Baker, J.; Blumberg, B.

J Infectious Diseases. 2003; 187(9): 1365-1376.

New research on the effect of temperature on MS symptoms.

Schwid, SR.; Goodman, AD.

MS Quarterly Report. 2003; 22: 12-16.

Impaired renal function in progressive multiple sclerosis.

Calabresi PA, Austin H, Racke MK, Goodman A, Choyke P, Maloni H, McFarland HF

Neurology.. 2002 December 1059 (11):1799-801. Epub 1900 01 01.

Quantitative functional measures in MS: what is a reliable change?

Schwid SR, Goodman AD, McDermott MP, Bever CF, Cook SD

Neurology.. 2002 April 2358 (8):1294-6. Epub 1900 01 01.

Infections and MS: clinical trials move to center stage.

Goodman AD, Miller DH

Neurology.. 2002 January 858 (1):7-8. Epub 1900 01 01.

Infections and Vaccinations in MS: Causative Role?

Goodman, AD.

MS Quarterly Report. 2002; 21(2): 12-15.

Benefit of interferon ?-1a on MSFC progression in secondary progressive MS.

Cohen, JA.; Cutter, GR.; Fischer, JS.; Goodman, AD.; (overall study co-PI and publication committee); et al.

Neurology. 2002; 9: 679-687.

Fatigue in multiple sclerosis: current understanding and future directions.

Schwid, SR.; Covington, M.; Segal, BM.; Goodman, AD.(corresponding author).

J Rehabil Res Devel. 2002; 39: 211-224.

Potential environmental and host participants in the early white matter lesion of adreno-leukodystrophy: morphologic evidence for CD8 cytotoxic T cells, cytolysis of oligodendrocytes, and CD1-mediated lipid antigen presentation.

Ito M, Blumberg BM, Mock DJ, Goodman AD, Moser AB, Moser HW, Smith KD, Powers JM

Journal of neuropathology and experimental neurology.. 2001 October 60 (10):1004-19. Epub 1900 01 01.

Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis.

American journal of ophthalmology.. 2001 October 132 (4):463-71. Epub 1900 01 01.

Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.

Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Jak AJ, Kniker JE, Kooijmans MF, Lull JM, Sandrock AW, Simon JH, Simonian NA, Whitaker JN

Archives of neurology.. 2001 June 58 (6):961-7. Epub 1900 01 01.

United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center.

Wolinsky JS, Narayana PA, Johnson KP,

Multiple sclerosis : clinical and laboratory research.. 2001 February 7 (1):33-41. Epub 1900 01 01.

Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients.

Cook, SD.; Quinless, JR.; Jotkowitz, A.; Beaton, P., The Neutralizing Antibody Study Group (Goodman, AD, Site P.I.).

Neurology. 2001; 57(6): 1080-1084.

Are quantitative functional measures more sensitive to worsening MS than traditional measures?

Schwid SR, Goodman AD, Apatoff BR, Coyle PK, Jacobs LD, Krupp LB, Miller AE, Wende KE, Brownscheidle CM, New York State Multiple Sclero

Neurology.. 2000 December 2655 (12):1901-3. Epub 1900 01 01.

Human herpesvirus 6-meningoencephalitis in an HIV patient with progressive multifocal leukoencephalopathy.

Ito M, Baker JV, Mock DJ, Goodman AD, Blumberg BM, Shrier DA, Powers JM

Acta neuropathologica.. 2000 September 100 (3):337-41. Epub 1900 01 01.

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group.

Johnson KP, Brooks BR, Ford CC, Goodman A, Guarnaccia J, Lisak RP, Myers LW, Panitch HS, Pruitt A, Rose JW, Kachuck N, Wolinsky JS

Multiple sclerosis : clinical and laboratory research.. 2000 August 6 (4):255-66. Epub 1900 01 01.

Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators.

Wolinsky JS, Narayana PA, Noseworthy JH, Lublin FD, Whitaker JN, Linde A, Gjörstrup P, Sullivan HC

Neurology.. 2000 May 954 (9):1734-41. Epub 1900 01 01.

The HHV6 paradox: Ubiquitous commensal or insidious pathogen?

Blumberg, B.; Mock, D.; Powers, J.; Chen, B.; Assouline, J.; Goodman, A.(corresponding author).

J Clinical Virol. 2000; 16: 159-178.

Linomide in relapsing and secondary progressive multiple sclerosis. I. Trial design and clinical results.

Noseworthy, JH.; Wolinsky, JS.; Lublin, FD.; (Goodman, AD.-site PI).

Neurology. 2000; 122: 871-882.

Intramuscular interferon Beta-1a therapy initiated during a first demyelinating event in multiple sclerosis.

Jacobs, LR.; Beck, RW.; Simon, JH.; et al (A. Goodman, site-PI).

NEJM. 2000; 343: 989-994.

A profile of multiple sclerosis: the New York State Multiple Sclerosis Consortium.

Jacobs LD, Wende KE, Brownscheidle CM, Apatoff B, Coyle PK, Goodman A, Gottesman MH, Granger CV, Greenberg SJ, Herbert J, Krupp L, Lava NS, Mihai C, Miller AE, Perel A, Smith CR, Snyder DH

Multiple sclerosis : clinical and laboratory research.. 1999 October 5 (5):369-76. Epub 1900 01 01.

Quantitative assessment of motor fatigue and strength in MS.

Schwid SR, Thornton CA, Pandya S, Manzur KL, Sanjak M, Petrie MD, McDermott MP, Goodman AD

Neurology.. 1999 September 1153 (4):743-50. Epub 1900 01 01.

Neuropsychologic status in multiple sclerosis after treatment with glatiramer.

Weinstein A, Schwid SR, Schiffer RB, McDermott MP, Giang DW, Goodman AD, Schwid SI

Archives of neurology.. 1999 March 56 (3):319-24. Epub 1900 01 01.

Selecting Relapsing Remitting Multiple Sclerosis Patients for Treatment: The Case for Early Treatment.

Rudick, RA.; Goodman, AD.; Herndon, RM.; Panitch, HS.

J Neuroimmunology. 1999; 98(1): 22-28.

Association of human herpesvirus 6 with the demyelinative lesions of progressive multifocal leukoencephalopathy.

Mock, DJ.; Powers, JM.; Goodman, AD.; et al.

J NeuroVirology. 1999; 5: 363-373.

Correlation of human herpesvirus 6 p41 and p 101 expression and oligodendroglial cell death in progressive multifocal leukoencephalopathy

Goodman AD; Mock DJ; Powers JM; Baker JV; Blumberg B;.

Annals of Neurology. 1999; 46(3): 488.

Association of human herpes virus 6 (HHV6) with demyelinating lesions.

Goodman AD; Mock D; Powers J et al.

J Neuroimmunology. 1998; 90(1): 66.

The measurement of ambulatory impairment in multiple sclerosis.

Schwid SR, Goodman AD, Mattson DH, Mihai C, Donohoe KM, Petrie MD, Scheid EA, Dudman JT, McDermott MP

Neurology.. 1997 November 49 (5):1419-24. Epub 1900 01 01.

Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b.

Schwid SR, Goodman AD, Mattson DH

Archives of neurology.. 1997 September 54 (9):1169-90. Epub 1900 01 01.

Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis.

Schwid SR, Petrie MD, McDermott MP, Tierney DS, Mason DH, Goodman AD

Neurology.. 1997 April 48 (4):817-21. Epub 1900 01 01.

Sporadic corticosteroid pulses and osteoporosis in multiple sclerosis.

Schwid SR, Goodman AD, Puzas JE, McDermott MP, Mattson DH

Archives of neurology.. 1996 August 53 (8):753-7. Epub 1900 01 01.

Can immunomodulatory effects of cyclophosphamide be conditioned in humans?

Giang, DW.; Goodman, AD. (study PI); Schiffer, RB.; Mattson, DH.; Cohen, N.; Ader, R.

Journal of Neuropsychiatry and Clinical Neuroscience. 1996; 8: 194-201.

Frequency of anti-nuclear antibodies in multiple sclerosis.

Barned S, Goodman AD, Mattson DH

Neurology.. 1995 February 45 (2):384-5. Epub 1900 01 01.

Clinical diagnosis of multiple sclerosis. The impact of magnetic resonance imaging and ancillary testing. Rochester-Toronto Magnetic Resonance Study Group.

Giang DW, Grow VM, Mooney C, Mushlin AI, Goodman AD, Mattson DH, Schiffer RB

Archives of neurology.. 1994 January 51 (1):61-6. Epub 1900 01 01.

Perils and pitfalls of magnetic resonance imaging in the diagnosis of multiple sclerosis. The Rochester-Toronto MRI Study Group.

Schiffer RB, Giang DW, Mushlin A, Ketonen L, Joy S, Kido D, Goodman AD, Mattson DH, Mooney C

Journal of neuroimaging : official journal of the American Society of Neuroimaging.. 1993 April 3 (2):81-8. Epub 1900 01 01.

The accuracy of magnetic resonance imaging in patients with suspected multiple sclerosis. The Rochester-Toronto Magnetic Resonance Imaging Study Group.

Mushlin AI, Detsky AS, Phelps CE, O'Connor PW, Kido DK, Kucharczyk W, Giang DW, Mooney C, Tansey CM, Hall WJ

JAMA.. 1993 269 (24):3146-51. Epub 1900 01 01.

Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. The Multiple Sclerosis Study Group.

Annals of neurology.. 1990 June 27 (6):591-605. Epub 1900 01 01.

Virus-specific cytotoxic T lymphocytes in multiple sclerosis: a normal mumps virus response adds support for a distinct impairment in the measles virus response.

Goodman AD, Jacobson S, McFarland HF

Journal of neuroimmunology.. 1989 May 22 (3):201-9. Epub 1900 01 01.

Virus specific cytotoxic T lymphocytes in multiple sclerosis.

McFarland, HF.; Goodman, AD.; Jacobson, S.

Annals of NY Acad. Med. 1988; 532: 273-279.

Autonomic neuropathy associated with autoimmune disease.

Gudesblatt M, Goodman AD, Rubenstein AE, Bender AN, Choi HS

Neurology.. 1985 February 35 (2):261-4. Epub 1900 01 01.

Neurosarcoidosis presenting as major depression.

Stiller, J.; Goodman, AD.; Kamhi, L.; Bender, MB.

Neurol Neurosurg Psych. 1984; 47: 1050.

Ratings & Comments

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.